Share on StockTwits

Medivation (NASDAQ:MDVN) set a new 52-week high during mid-day trading on Wednesday, Analyst RN reports. The stock traded as high as $87.46 and last traded at $83.77, with a volume of 5,383,115 shares. The stock had previously closed at $75.78.

MDVN has been the subject of a number of recent research reports. Analysts at UBS AG raised their EPS on shares of Medivation in a research note to investors on Wednesday. They now have a “buy” rating and a $93.00 price target on the stock. Separately, analysts at Wedbush raised their price target on shares of Medivation to $118.00 in a research note to investors on Wednesday. Finally, analysts at Brean Capital raised their price target on shares of Medivation from $72.00 to $100.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $84.27.

In other Medivation news, CEO David Hung unloaded 150,000 shares of Medivation stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $73.50, for a total transaction of $11,025,000.00. Following the transaction, the chief executive officer now directly owns 950,204 shares in the company, valued at approximately $69,839,994. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Medivation has a one year low of $41.89 and a one year high of $79.46. The stock’s 50-day moving average is $68.22 and its 200-day moving average is $60.82. The company’s market cap is $6.276 billion.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.08. The company had revenue of $108.50 million for the quarter, compared to the consensus estimate of $60.13 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. On average, analysts predict that Medivation will post $-0.70 earnings per share for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.